Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12065448 Heteroaryl plasma kallikrein inhibitors

Patent 12065448 was granted and assigned to Takeda Pharmaceutical Company on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Takeda Pharmaceutical Company

0

Current Assignee

Takeda Pharmaceutical Company

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jeremy Mark Travins0

John Mark Ellard0

Alastair Rae0

Sarah Jocelyn Fink0

Nikolaos Papaioannou0

Date of Patent

August 20, 2024

0

Patent Application Number

178317160

Date Filed

June 3, 2022

0

Patent Citations

US Patent 11352356 Inhibitors of plasma kallikrein and uses thereof

0

US Patent 11787796 Plasma Kallikrein inhibitors and uses thereof

0

US Patent 11370803 Heteroaryl plasma kallikrein inhibitors

0

US Patent 7166596 Heterocyclic aromatic compounds useful as growth hormone secretagogues

0

US Patent 8153658 Piperidine derivative or salt thereof

0

US Patent 10259803 Therapeutic inhibitory compounds

0

US Patent 10301284 Therapeutic inhibitory compounds

0

US Patent 10730874 Inhibitors of plasma kallikrein and uses thereof

0

Patent Primary Examiner

0

CPC Code

0

0

Patent abstract

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12065448 Heteroaryl plasma kallikrein inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool